Knopp Biosciences LLC, a drug discovery and development company, announced yesterday that it has commenced phase two dose-ranging
clinical trial of oral dexpramipexole in moderate-to-severe eosinophilic asthma.
The Phase 2a BALANCED study is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging
trial in biopsy-confirmed patients with NASH.
Ionis and Akcea plan to conduct a Phase II dose-ranging
study for each drug, to choose the optimal dose and evaluate alternative dose schedules for the Phase III study.
Austin reported are part of an ongoing dose-ranging
evaluation of 3-180 mg of ofatumumab for relapsing-remitting MS.
(Nasdaq:CHTP), Charlotte, N.C., hasannounced that a preliminary analysis of its dose-ranging
exploratory Phase II trial of CH-4051, a non- metabolized antifolate, in patients with rheumatoid arthritis (RA) who experience an inadequate response to methotrexate (MTX) treatment indicates that CH-4051 did not demonstrate superior efficacy to methotrexate in the dose range evaluated.
Over the 12-week dose-ranging
study, subjects taking 6 mg of the drug daily lost a mean of 5 kg, compared with a mean of 1 kg for patients taking a placebo, reported Dr.
Sanofi-aventis recently announced that the results of the TREK dose-ranging
study for its new injectable anticoagulant, AVE5026, were presented at the 49th annual meeting of the American Society of Haematology (ASH) in Atlanta.
The Phase I/II dose-ranging
trial will take place at The Riverside Hospital in Ottawa, and will involve 50 dyslipidemic patients (patients with low HDL and high LDL).
Research: In a randomized, double-blind, placebo-controlled, dose-ranging
study, 362 women between 18 and 65 years of age who had been diagnosed with IBS (per Rome II criteria) received placebo or freeze-dried, encapsulated Bifantis once daily for four weeks.
There are new chapters on contexts for clinical trials, statistical perspectives, and dose- finding and dose-ranging
Tokyo, Japan, Sept 6, 2005 - (JCNN) - Sosei, a Japanese biopharmaceutical company, announced on September 5 that its wholly owned UK subsidiary Arakis has started a phase IIb dose-ranging
study of AD 452, an investigational drug for the treatment of rheumatoid arthritis (RA).